尼拉帕里布和基化疗之间的真实世界TRAE关联
Linli Wang1, Jieli Zhou2, Haibin Wang2
1First Clinical College, Gannan Medical University, Ganzhou, China.
Frontiers in oncology
|July 2, 2024
概括
与白金基化疗相比,晚期卵巢癌患者耐受得很好,经历了较少的与治疗相关的不良事件,特别是贫血和中性粒细胞数量的减少. 在化疗后的尼拉帕里布治疗期间,建议对血液学不良反应进行仔细监测.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 泌尿生殖系统癌症是什么
背景情况:
- PARP 抑制剂 (PARPi) 和剂共享DNA损伤修复通路机制,这表明它们具有重叠的敏感性.
- 临床前数据表明,响应基化疗的患者也可能从PARPi中受益.
研究的目的:
- 在晚期卵巢癌患者中,评估基化疗 (PBC) 和尼拉帕里布之间与治疗相关的不良事件 (TRAE) 的关联.
- 评估尼拉帕里布在以为基础的化疗后的实际安全性.
主要方法:
- 从2020年1月到2023年8月,对40名晚期卵巢癌患者进行了回顾性分析,这些患者接受了niraparib (维护或救援) 治疗.
- 在最后一个基化疗周期和尼拉帕里布治疗期间记录的不良事件.
- 利用费舍尔的精确测试来对TRAE进行相关性分析.
主要成果:
- 与化疗 (70%) 相比,尼拉帕里布 (40%) 的TRAE总等级≥3显著降低,特别是贫血 (20%vs45%) 和中性粒细胞数量的减少 (17.5%vs57.5%).
- 任何级别的TRAE也显著降低了尼拉帕里布 (75%) 与化疗 (100%),包括白细胞数量减少 (47.5%与87.5%),红细胞数量减少 (57.5%与92.5%),贫血 (55%与87.5%),和中性粒细胞数量减少 (35%与85%).
- 在尼拉帕里布治疗期间没有发现新的安全信号.
结论:
- 患有晚期卵巢癌的患者耐受得很好,与之前的基化疗相比,TRAE的发病率显著降低,包括贫血和中性缺血.
- 建议在基化疗期间经历≥3级血液学不良事件后接受niraparib的患者密切监测和管理血液学不良反应.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
158
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
158
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
192
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
192
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
220
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
220
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K


